Pulmonary Embolism and PCT. PE-PCT Study
Study Details
Study Description
Brief Summary
The clinical manifestations of pulmonary embolism vary greatly from the absence of specific clinical symptoms to cardiogenic shock or cardiac arrest. Clinical form of EP represented by "lung superinfection", also called "pulmonary embolism superinfected" is common and represents up to 30% of initial clinical presentations; she been few evaluations in clinical research. The reality of the bacterial infection remains controversial and the clinical presentation often leads to the prescription of empirical antibiotic therapy, often unnecessary in many cases. Number of antibiotic prescriptions are probably inappropriate.
Fever has long been recognized as a sign associated with pulmonary embolism. Stein et al reported a temperature above 37.5 ° C on 50% of patients with acute pulmonary embolism without actually clarified whether this was related to temperature with a pulmonary embolism or other associated cause. Murray et al estimated that greater than 38 ° C was explained by pulmonary embolism in 57.1% of patients while in the PIOPED study, only 14% of patients had fever with no other cause identified as pulmonary embolism. Fever due to pulmonary embolism is often low intensity (often less than 38.3) and of short duration, with a peak on the day of pulmonary embolism and a gradual decrease of about 1 week. The pathophysiology of fever in pulmonary embolism has not yet was completely clarified. It is suggested that a combination of several factors involved pyrogenic myocardial tissue necrosis and releasing pro-inflammatory cytokines, hemorrhage, vascular irritation or inflammation, atelectasis or local superinfection.
Since 2004, the PCT has become a marker helping the initiation of antibiotic therapy in patients with community-acquired pneumonia. This is especially verified in patients admitted for acute exacerbation of chronic obstructive bronchitis. In the latter case, the use of PCT reduces inappropriate antibiotic prescribing. Thus helping the clinician by measuring biomarkers such as PCT is based on writing an algorithm leading or not to use antibiotics.
The use of an algorithm involving the PCT could just as for infectious pneumonia or COPD, of interest in the febrile pulmonary embolism to distinguish febrile forms related to bacterial infections febrile forms of EP to other causes.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
The investigators propose to realize a single-center prospective, randomized, parallel group, to compare two groups of patients admitted with febrile pulmonary embolism . In the first group of patients, the use of antibiotics will be guided by clinical (clinical group). In the second group, the use of antibiotics will be guided by the algorithm (PCT group). The guided by the PCT algorithm is only given aid the clinician in the therapeutic management without its application only requires the doctor in charge of the patient. So if your doctor may advocate (or deemed necessary) to continue (or start) antibiotics even if the PCT algorithm would allow him to stop (or not initiate).
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: clinical group In the first group of patients, the use of antibiotics will be guided by clinical (clinical group). |
Procedure: Procalcitonin algorithm
Procalcitonin algorithm (usually used for lower respiratory tract) guide antibiotic therapy
|
| Other: PCT group In the second group, the use of antibiotics will be guided by the algorithm (PCT group). |
Procedure: Procalcitonin algorithm
Procalcitonin algorithm (usually used for lower respiratory tract) guide antibiotic therapy
|
Outcome Measures
Primary Outcome Measures
- Percentage of patient treated by antibiotics in each group [at day 1]
Secondary Outcome Measures
- Percentage of death [at day 1]
- Percentage of antibiotics stop [at day 1]
- Rate of new hospitalization during the following month [at 1 month]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age over 18 years
-
CT diagnosis of pulmonary embolism
-
Temperature> 37.8 ° C
-
About affiliated to the social security
-
Prior agreement with the patient signing a consent
Exclusion Criteria:
-
Pregnant Woman
-
Refusal of the patient
-
Pulmonary Neoplasia
-
Antibiotic ongoing for more than 24 hours at the time of diagnosis of pulmonary embolism
-
Cardiogenic shock (hypotension with mean arterial pressure less than 65 bpm)
-
Suspicion of infection other than lung associated (associated urinary tract infection, prostatitis, ENT infection, sinusitis ...)
-
Patient under guardianship
-
Patients unable to give consent
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | CHU Clermont-Ferrand | Clermont-Ferrand | France | 63003 |
Sponsors and Collaborators
- University Hospital, Clermont-Ferrand
- Thermo Fisher Scientific, Inc
Investigators
- Principal Investigator: Farès MOUSTAFA, University Hospital, Clermont-Ferrand
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CHU-0203
- 2014-A00046-41